Tilray® Announces Agreement with Grow Pharma to Import and Distribute Medical Cannabis Products in the United Kingdom
February 09 2021 - 6:00AM
Business Wire
Grow Pharma will distribute Tilray’s GMP-certified medical
cannabis products across the UK
New UK agreement gives doctors and patients access to a
sustainable supply of Tilray’s pharmaceutical-grade medical
cannabis products
Tilray Inc. (NASDAQ: TLRY), a global pioneer in cannabis
research, cultivation, production, and distribution, today
announced it has established an agreement with Grow Pharma to
import and distribute Tilray’s medical cannabis products into the
United Kingdom (UK). This agreement allows Tilray to provide
authorized UK patients in need with a locally maintained supply of
medical cannabis solutions.
Tilray expects to have a range of GMP-certified, medical
cannabis products available for patients in the UK by March 2021.
Patients looking to use medical cannabis will have access to Tilray
products in the UK by obtaining prescriptions through private
practice or the National Health Service (NHS).
Brendan Kennedy, Tilray’s Chief Executive Officer, said, “This
partnership with Grow Pharma provides patients in need access to a
sustained supply of GMP-certified, high-quality medical cannabis
and is an important step in improving access in the UK. Tilray will
continue to advocate for reasonable patient access to medical
cannabis in Europe and countries around the world.”
Sascha Mielcarek, Managing Director of Tilray Europe, said, “As
demand continues to ramp up in the UK, Tilray is well-positioned to
be a leading supplier of medical cannabis products. Regulations are
progressing as more and more countries across Europe are
recognizing the benefits of medical cannabis and its potential to
improve patients’ quality of life. We’re pleased to reaffirm our
commitment to delivering medical cannabis to patients in the UK and
look forward to offering a variety of GMP-certified,
pharmaceutical-grade products in the coming months.”
Pierre van Weperen, Chief Executive Officer of Grow Pharma,
said, “We’re proud to join forces with Tilray and provide patients
in need with a secure and sustainable supply of the highest-quality
medical cannabis products in the UK.”
About Grow Pharma
Grow Pharma is a leading UK medical cannabis distributor, part
of the Grow Group. Grow Group PLC exists to unlock the medical
potential of cannabis for those who need it though three business
units: Grow Pharma, Grow Trading and Grow Biotech. Grow Pharma
works with the producers of the best cannabis-based medicines and
helps them introduce their products in new markets like the U.K.
and Ireland, creating long-term value for them and offering
solutions for patients. The Grow Pharma team also focuses on
supporting clinics and individual healthcare professionals and
through our partnership with IPS Specials Pharma we work with the
best importer, distributor and pharmacy in the country to deliver
the medication to patients. Ultimately, all Grow Group activities
are aimed at improving patient access to cannabis medicines.
https://growgroupplc.com
About Tilray®
Tilray is a global pioneer in the research, cultivation,
production, and distribution of cannabis and cannabinoids currently
serving tens of thousands of patients and consumers in 17 countries
spanning five continents.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995 and "forward-looking information" within the meaning of
Canadian securities laws, or collectively, forward-looking
statements. Forward-looking statements in this press release may be
identified by the use of words such as, "may", "would", "could",
"will", "likely", "expect", "anticipate", "believe, "intend",
"plan", "forecast", "project", "estimate", "outlook" and other
similar expressions. Forward-looking statements are not a guarantee
of future performance and are based upon a number of estimates and
assumptions of management in light of management's experience and
perception of trends, current conditions, and expected
developments, as well as other factors that management believes to
be relevant and reasonable in the circumstances, including
assumptions in respect of current and future European market
conditions, the current and future regulatory environment and
future approvals and permits. Actual results, performance, or
achievement could differ materially from that expressed in, or
implied by, any forward-looking statements in this press release,
and, accordingly, you should not place undue reliance on any such
forward-looking statements, and they are not guarantees of future
results. Please see the heading "Risk Factors" in Tilray's
Quarterly Report on Form 10-Q, which was filed with the Securities
and Exchange Commission on November 9, 2020, for a discussion of
the material risk factors that could cause actual results to differ
materially from the forward-looking information. Tilray does not
undertake to update any forward-looking statements that are
included herein, except in accordance with applicable securities
laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210209005404/en/
Tilray Global: Berrin Noorata news@tilray.com
To request an interview opportunity: Media Amy Bonwick
647-515-3748 amy@pomppr.com
Ranjit Dhatt 647-890-2445 ranjit@pomppr.com
Investors Raphael Gross 203-682-8253
Raphael.Gross@icrinc.com
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Sep 2023 to Sep 2024